Results 301 to 310 of about 260,886 (316)

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of Thoracic Oncology, 2018
Scott Gettinger, Matthew D Hellmann, Jonathan W Goldman   +2 more
exaly  

GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis

Biomedicine and Pharmacotherapy, 2017
Qiong Chen
exaly  

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Journal of Thoracic Oncology, 2015
Jianhua Zhan, Shaodong Hong, Yanna Tang   +2 more
exaly  

miR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells

Molecular and Cellular Biochemistry, 2014
Li Wan
exaly  

MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1

Tumor Biology, 2014
Hongda Lu, Zhan Yan
exaly  

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology, 2015
E F Smit, T De Pas, M -J Ahn
exaly  

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

Annals of Oncology, 2010
Martin Reck, A Anthoney, A -R Hanauske   +2 more
exaly  

Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

International Journal of Radiation Oncology Biology Physics, 1999
Mary V Graham, James A Purdy, B Emami
exaly  

NSCLC—platinum or not

Lung Cancer, 2005
Nikos Androulakis, Vassilis Georgoulias
openaire   +1 more source

Panitumumab in NSCLC

Oncology Times, 2004
openaire   +1 more source